Skip to main content
. 2022 Dec 1;9:1058235. doi: 10.3389/fmed.2022.1058235

FIGURE 1.

FIGURE 1

Kaplan–Meier of 28-day mortality after Adrecizumab/placebo infusion, based on circulating dipeptidyl peptidase 3 (cDPP3) stratification. Data is displayed for the original intention to treat (ITT) analysis (15) (A) and the cDPP3 <50 ng/mL subgroup (B). Both Adrecizumab dosing groups were combined. Crosses represent censored patients.